In an interview at the 2021 Annual Meeting of The European Society for Blood and Marrow Transplantation, Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, discusses the fludarabine-amsacrine-cytarabine (FLAMSA) approach for patients with refractory AML. No treatments are curative for patients with relapsed/refractory AML, but we should not neglect the option of allogeneic stem cell transplantation. Available evidence has demonstrated 30% to 35% leukemia-free survival at 2 years. Professor Mohty notes that we can achieve long-term survival in this subgroup of patients using this approach.